Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
November 07, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Endoscopy Procedures Market Size worth $53.19 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
September 26, 2023 10:35 ET
|
The Insight Partners
Pune, India, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Endoscopy is a minimally invasive procedure used to examine a person's digestive tract through the mouth, anus, or in small incisions. The procedure...
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Enteral and Parenteral Medical Nutrition Market Report – Reach $25.47 Billion, Globally by 2028 with 6.8% CAGR During 2023-2028 | The Insight Partners
June 20, 2023 10:15 ET
|
The Insight Partners
Pune, India, June 20, 2023 (GLOBE NEWSWIRE) -- According to our latest study on "Enteral and Parenteral Medical Nutrition Market Size Report, Forecast to 2028 – COVID-19 Impact and Global Analysis –...
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023 07:00 ET
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023 06:59 ET
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...